Bildkälla: Stockfoto

Cantargia: New Biomarker Results in Pancreatic Cancer - Redeye

Redeye believes the new biomarker results with nadunolimab to be presented at the AACR Annual Meeting 2023 validate the scientific understanding of nadunolimab.

Redeye believes the new biomarker results with nadunolimab to be presented at the AACR Annual Meeting 2023 validate the scientific understanding of nadunolimab.
Börsvärldens nyhetsbrev
ANNONSER